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Abstract
Achieving high-efficiency tumor targeting after systemic delivery is a considerable challenge facing oncolytic
gene therapists. Efficient retargeting should be combined with efforts to improve in vivo safety, reduce hepa-
totoxicity, minimize off-target interactions, and improve antitumoral potency and efficacy. We previously de-
scribed the successful retargeting of adenovirus serotype 5 (Ad5) to avb6, an integrin that is highly overexpressed
in numerous human carcinomas. In this study, we have further modified this construct by introducing mutations
that ablate coxsackievirus–adenovirus receptor (CAR) binding and putative interactions with factor IX (FIX)/
C4b-binding protein (C4BP). We have found that the resulting vector, Ad5-477dlTAYTA20, displays a desirable
in vivo safety profile. This vector does not agglutinate human erythrocytes, fails to cause thrombocytopenia after
intravenous delivery, has limited induction of proinflammatory cytokines, and results in low-level toxicity
(aspartate aminotransferase/alanine aminotransferase) when compared with Ad5-EGFPWT. Furthermore, it has
reduced accumulation in Kupffer cells (1 hr) and limited hepatocyte transduction at later time points (24 and
96 hr). The parental vector, Ad5-EGFPA20, also displayed many of these desirable properties. As a result of the
improved safety profile of both A20-modified vectors, we escalated the dose from 2 · 1010 to 4 · 1010 viral
particles in an antitumoral efficacy study. We observed improvements in reducing percent tumor growth at
early time points (96 hr) when compared with Ad5-EGFPWT, although increasing the dose did not affect the
therapeutic outcome beneficially. On completion of the experiment, we detected increased E1A staining in the
tumors of all A20-treated groups and we determined that E1A expression was localized largely within avb6
+
tumor cells. However, in spite of apparently efficient tumor transduction, this did not result in enhanced
antitumoral efficacy as the virus failed to disseminate effectively throughout the tumor mass, presumably due to
physical intratumoral restrictions. This highlights a remaining challenge that needs to be overcome before such
vectors can be developed for future cancer gene therapy applications.
Introduction
Adenoviral (Ad) vectors are used widely in anticancergene therapy applications. However, limited uptake in
malignant tissue represents a major obstacle to the use of
therapeutic Ads for the treatment of cancer. Attempts to target
disseminated metastasis after intravenous Ad delivery are
hampered by undesirable interactions between the virus and
various circulatory components (Coughlan et al., 2010). For
example, direct interactions with coagulation factors (Parker
et al., 2006; Kalyuzhniy et al., 2008; Waddington et al., 2008),
erythrocytes (Carlisle et al., 2009; Seiradake et al., 2009),
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or antibodies (natural and neutralizing) contribute to the
off-target sequestration of the vector and can preclude effi-
cient delivery of the therapeutic load to tumors. In particular,
a high-affinity interaction between the adenovirus serotype 5
(Ad5) hexon and coagulation factor X (FX) results in signifi-
cant hepatocyte transduction and toxicity, and limits extra-
hepatic delivery in rodent models (Kalyuzhniy et al., 2008;
Waddington et al., 2008). Resident macrophages of the retic-
uloendothelial system also rapidly scavenge, sequester, and
eliminate virus from the circulation (Lieber et al., 1997). The
combination of these interactions can trigger systemic pro-
inflammatory cytokine responses and lead to dose-limiting
vector-related toxicity. Thus, it is assumed that a vector that
displays enhanced tumor delivery, an improved systemic
safety profile, and reduced liver tropism would have great
potential for future clinical development. Such refined selec-
tivity should permit vector dose escalation to allow maximal
delivery to malignant tissue, with minimal side effects.
To overcome the issue of poor in vivo transduction, ex-
tensive attempts have been made to retarget Ad vectors to
tumor cell markers (Coughlan et al., 2010). The integrin avb6
represents an attractive target for tropism-modified thera-
peutic Ads because expression in humans is restricted to
epithelial remodeling events, such as wound healing and
carcinogenesis, and it is largely undetectable in normal hu-
man epithelia (Breuss et al., 1995). Conversely, it is over-
expressed in numerous human carcinomas (Ahmed et al.,
2002; Sipos et al., 2004; Thomas et al., 2006; Hazelbag et al.,
2007), where expression correlates with increased tumor cell
migration, invasion, and advanced disease states (Ahmed
et al., 2002; Bates et al., 2005; Elayadi et al., 2007). Con-
veniently, avb6-specific targeting peptides currently exist
and have been validated extensively in vivo (Elayadi et al.,
2007; Hausner et al., 2007; Saha et al., 2010). In contrast, the
native Ad5 receptor, the coxsackievirus–adenovirus receptor
(CAR), has a broad expression profile in human tissue
(Bergelson et al., 1998). CAR also is thought to be poorly
expressed in certain primary human tumor specimens ( Jee
et al., 2002; Rauen et al., 2002), and its downregulation has
been associated with tumor progression and poor prognosis
(Matsumoto et al., 2005; Anders et al., 2009). Such studies
suggest that CAR may be dispensable for cancer-targeting
strategies. In support of this, the finding that human, but not
murine, erythrocytes express CAR on their surface empha-
sizes the importance of developing CAR-independent re-
targeting strategies, or at least the use of relevant in vivo
models, with which to study tumor delivery (Carlisle et al.,
2009; Seiradake et al., 2009).
However, CAR-binding ablation strategies alone have not
proven useful in limiting the extensive liver transduction of
Ad5 in vivo, nor in altering the overall biodistribution of the
vector (Alemany and Curiel, 2001; Martin et al., 2003; Nicol
et al., 2004). It has become clear that coagulation factors,
notably FX, mediate hepatocyte transduction via heparan
sulfate proteoglycans (HSPGs) after intravenous delivery
(Parker et al., 2006; Waddington et al., 2008). Shayakhmetov
and colleagues previously described an Ad5 mutant, Ad5mut,
featuring a set of fiber mutations (Y477A and a TAYT dele-
tion), which they proposed abrogated binding to factor IX
(FIX) and C4b-binding protein (C4BP) (Shayakhmetov et al.,
2005). When compared with Ad5, this vector was reported to
display significantly reduced liver transduction and toxicity,
low-level cytokine induction, and a failure to colocalize with
Kupffer cells (KCs) after intravenous delivery.
We previously have described Ad5-EGFPA20, an HI loop-
modified, avb6-retargeted vector, which showed improved
tumor uptake accompanied by reduced liver transduction
and hepatotoxicity when compared with Ad5 after intrave-
nous delivery (Coughlan et al., 2009). Herein, we sought to
improve on this prior construct by introducing an additional
set of mutations to ablate CAR binding, in addition to
putative fiber–FIX/C4BP interactions (Shayakhmetov et al.,
2005). In the present study, we have investigated whether
Ad5-477dlTAYTA20 retains or improves on the desirable
in vivo characteristics of the parental vector Ad5-EGFPA20.
We have assessed its safety profile by measuring the release
of proinflammatory cytokines, its interaction with/effect on
various hematological cells, its accumulation in the liver at
early and late time points after intravenous injection, and the
induction of hepatotoxicity (aspartate aminotransferase
[AST]/alanine aminotransferase [ALT]). We have also de-
termined its therapeutic efficacy and compared it with Ad5-
EGFPWT and Ad5-EGFPA20, using a xenograft tumor model.
Materials and Methods
Cell lines
Human carcinoma cell lines BT-20 and DX3-b6 and their
growth requirements have been described (Coughlan et al.,
2009). Human breast adenocarcinoma line MCF10-CA1a (a
kind gift from S. Santner, Karmanos Cancer Institute, Detroit,
MI) was grown in Dulbecco’s modified Eagle’s medium
(DMEM). Chinese hamster ovary cell lines CHO-K1 (Amer-
ican Type Culture Collection [ATCC], Manassas, VA), CHO-
CAR (a kind gift from G. Santis, King’s College London,
London, UK), and CHO-pgsA745 were cultured in DMEM.
CHO-pgsE606 and CHO-pgsF17 cells were grown in Ham’s
F12 medium. HEK293-b6 and JH293-b6 cells were generated
by retroviral transduction, stably introducing b6 cDNA as
described previously (Marshall et al., 1991). High b6-expressing
cells were selected and maintained in puromycin-containing
medium (5lg/ml) and isolated by fluorescence-activated cell
sorting (FACS), using a MoFlo FACS machine (Beckman
Coulter, Brea, CA) and Summit version 4.0 software. Sorting
was performed at the FACS Laboratory of the Cancer Re-
search UK London Research Institute (London, UK).
Flow cytometry
Surface receptors (CAR/avb6) were detected by flow cy-
tometry as previously described (Coughlan et al., 2009). Viral
enhanced green fluorescent protein (EGFP) gene transfer and
competition gene transfer assays were quantified by acqui-
sition of EGFP fluorescence in FL1-H (fluorescence channel 1
height) by flow cytometry, using a FACSCalibur flow cyt-
ometer (BD Biosciences, San Jose, CA) and CellQuest Pro
software for analysis. Blood samples were taken from mice
6 and 24 hr postinjection of virus and serum was separated,
using Sarstedt CB 300 capillary tubes with clot activator
(Sarstedt, Nu¨mbrecht, Germany). Serum levels of IL-6,
RANTES (regulated on activation, normal T cell expressed
and secreted), interferon (IFN)-c, tumor necrosis factor
(TNF)-a, and IL-12(p70) were quantified by multiplex
cytometric bead assay, according to the manufacturer’s
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instructions (FlowCytomix; Bender MedSystems, Austria).
Calculations and analysis of results were performed with
FlowCytomix Pro 2.2 software.
Construction of expression vectors and recombinant
protein purification
The pQE30 expression plasmid, containing Ad5 knob
and the A20-modified knob protein, has been described
(Coughlan et al., 2009). pQE-KnobA20 was used as a template
for mutagenic PCR to introduce the Y477AdlTAYT modifi-
cation, using primers MutY477A-For (5¢-TTCCTGGACC
CAGAAGCTTGGAACTTTAGAAAT-3¢) and MutY477A-Rev
(5¢-ATTTCTAAAGTTCCAAGCTTCTGGGTCCAGGAA-3¢), the
underlined portions of the primer sequences indicate the site
of modification introduced. After mutagenic PCR, DpnI
(Promega, Madison, WI) was used to digest the residual
template DNA, leaving newly synthesized and unmethylated
DNA intact. Splicing by overlapping extension (SOEing) PCR,
a PCR-based system for generating chimeric gene sequences
without reliance on restriction sites (Horton, 1995), was used
to delete the TAYTmotif (12 nucleotides). Fragments flanking
this site within pQE30-KnobY477AA20 were amplified in two
separate PCRs, using the primers F5-For (5¢-TTTAAGGA
TCCGGTGCCATTACAGTAGGAA-3¢) and dlTAYT477-Rev
(5¢-CAACAGCGTTGCCTTCAGTAAGAGCTC-3¢) to gener-
ate the left arm, and dlTAYT477-For (5¢-CTGAAGGCAACG
CTGTTGGATTTATG-3¢) with F5-Rev (5¢-TATATAAGCTTA
TTCTTGGGCAATGTATGA-3¢) to generate the right arm. An
intermediate reactionwasperformed in the absence of primers
for 15 cycles to permit hybridization of the complementary,
overlapping regions within the 5¢ region of the primer. The
resulting PCR product was then subjected to a final round of
PCR, using F5-For and F5-Rev, designed to amplify the entire
fragment. Products were sequenced, ligated into the pQE30
expression plasmid, and subsequently transformed into Es-
cherichia coli SG13009 for recombinant protein production as
described (Coughlan et al., 2009).
Characterization of recombinant knob proteins
Knob477dlTAYTA20 features a Y477A mutation in the fiber
that ablates binding to CAR (Kirby et al., 1999) and a avb6-
selective peptide ligand within the HI loop. CHO-CAR cells
(1 · 105) were preincubated with increasing concentrations of
KnobA20 or Knob477dlTAYTA20 (ranging from 0.001 to
100 lg/105 cells) as described (Coughlan et al., 2009).
Knob477dlTAYTA20 was used to inhibit the binding of an
avb6-specific antibody, 53A.2 (Coughlan et al., 2009). BT-20
cells (low CAR, high avb6) were incubated with increasing
concentrations of protein (0.0001 to 10 lg/105 cells), after
which unbound avb6 was detected by flow cytometry
(Coughlan et al., 2009).
Generation of Ad genomes, virus production
and titration
Fully replication-competent viruses were generated by
two-step homologous recombination in yeast, using a
strategy described in detail elsewhere (Coughlan et al.,
2009). To create the Ad5-477dlTAYTA20 backbone (which
also has EGFP in place of E3 6.7K/gp19K), pKnob477dl-
TAYTA20-TOPO was digested with PflMI and MscI, and
the fragment containing the modifications was subcloned
into the fiber shuttle vector pIVA20 (Coughlan et al., 2009).
All viruses were purified by double CsCl banding. The
non-CAR-binding virus, Ad5-477dlTAYTA20, was ampli-
fied on HEK293-b6 cells. Infectious titers (plaque-forming
units [PFU]/ml) of Ad5-EGFPWT, Ad5-EGFPA20, and Ad5-
477dlTAYTA20 were determined by titrating viruses in
parallel on quadruplicate plates of JH293-b6 cells
(Coughlan et al., 2009). Fluorescently labeled viral parti-
cles were generated with an Alexa Fluor 488 protein-
labeling kit (Invitrogen, Carlsbad, CA) according to a
previously established protocol (Bradshaw et al., 2010).
Labeled particle titers were determined with a micro-
bicinchoninic acid (BCA) assay (Bio-Rad, Hercules, CA)
Table 1. Antibodies Used for Immunohistochemistry
Antibody
specificity Isotype Fixation Clone
Final
concentration Source Secondary antibodya Application
avb6 Ms IgG 10% formalin
Retrieval: Pepsin
62G2 0.5 lg/ml Astra
Zeneca
M.O.M. basic kit{ IHC-P
CD31 Rt IgG2a 10% formalin
Retrieval: Sodium
citrate (pH 6.0)
SZ31 10 lg/ml Histonova Biotinylated Rb a-Rt
(3 lg/ml)
IHC-P
Cytokeratin
(pan)
Ms IgG 10% formalin
Retrieval: 37C,
proteinase K
AE1/AE2 1:20 dilution Abcam M.O.M. basic kit{ IHC-P
F4/80 Rt IgG2a 4% PFA CI:A3-1 20 lg/ml Abcam Gt a-Rt IgG Alexa 594 IHC-Fr
E1A (13 S-5) Rb pAb Acetone (- 20C) N/A 1:100 dilution Santa Cruz Gt a-Rb IgG Alexa 488 IHC-Fr
E1A (13 S-5) Rb pAb 10% formalin
Retrieval: sodium
citrate (pH 6.0)
N/A 1:500 dilution
(0.4 lg/ml
final)
Santa Cruz ABC Universal Elite kit{ IHC-P
MARCO
(SR-A)
Rt IgG 4% PFA ED31 2 lg/ml Bachem Gt a-Rt IgG Alexa 594 IHC-Fr
Ab, antibody; Gt, goat; IHC-Fr, immunohistochemistry frozen; IHC-P, immunohistochemistry paraffin; Ms, mouse; N/A, not applicable;
PFA, paraformaldehyde; Rb, rabbit; Rt, rat.
Note: Isotype control antibodies were as follows: mouse IgG (Dako), rat IgG2a (Abcam), rat IgG1 (Vector Laboratories), and rabbit IgG
(Santa Cruz Biotechnology).
aAntibody was provided as part of the {mouse-on-mouse (M.O.M.) basic kit or the {ABC Universal Elite kit (both from Vector
Laboratories).
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and viral particle (VP) titers were calculated according to
1 lg = 4 · 109 particles.
Hemagglutination of human erythrocytes
We isolated erythrocytes from human blood samples, ob-
tained from volunteers with approval of the local ethics
committee at University of Glasgow. Positive control samples
were treated with 0.1% Triton X-100 and negative controls
with phosphate-buffered saline (PBS). Hemagglutination
was determined according to a previously described method
(Cichon et al., 2003).
Viral gene transfer with or without FIX, FX,
and modified heparins
Standard viral transduction and cytotoxicity assays were
performed exactly as described (Coughlan et al., 2009). CHO-
K1 or CHO-CAR cells (1 · 105) were seeded in 24-well plates
and allowed to attach overnight. Triplicate wells were then
infected for 2 hr at 37C at a multiplicity of infection (MOI) of
10 (PFU/cell) with Ad5-EGFPWT, Ad5-EGFPA20, or Ad5-
477dlTAYTA20 alone, or mixed with physiological concen-
trations of FIX (5lg/ml; Cambridge Biosciences, Cambridge,
UK), FX (10lg/ml; Cambridge Biosciences), FIX/FX in
addition to porcine heparin, de-N-sulfated heparin, or de-O-
sulfated heparin (25lg/ml; Sigma-Aldrich, St. Louis, MO),
or virus with heparin/modified heparins alone (25lg/ml).
Transduction assays were also performed in CHO-pgsA745,
CHO-pgsE606, and CHO-pgsF17 cells, which are defective in
heparan sulfate glycosaminoglycan (HS-GAG) synthesis
(Esko et al., 1987), O- and particularly N-sulfate HS side-
chain synthesis (Bame and Esko, 1989), or lack 2-O-sulfated
residues (Bai and Esko, 1996), respectively. After incubation,
cells were washed twice in PBS, medium was replaced with
fresh culture medium, and transduction was allowed to
proceed for *22 hr under standard conditions. EGFP fluo-
rescence, detected by flow cytometry, was the end point for
these assays.
In vivo animal experiments
Animal experiments using immunocompetent BALB/c
male mice (6–8 weeks) were carried out at the facility of the
Institut d’Investigacio´ Biome`dica de Bellvitge (IDIBELL),
within the Institut Catala` d’Oncologia (ICO, Barcelona,
Spain), in accordance with the regulations of the IDIBELL
Ethics Committee for Animal Experimentation. Experiments
performed in tumor-bearing animals were carried out at the
Barts Cancer Institute under Home Office regulations. For bio-
distribution studies, animals injected intravenously with 4·1010
VP of Ad5-EGFPWT, Ad5-EGFPA20, or Ad5-477dlTAYTA20
were killed 1, 24, or 96 hr postinjection. Viral genomes from
tissue were evaluated by quantitative PCR (qPCR) as
described previously (Coughlan et al., 2009). To identify
virus-interacting cells in the liver and spleen at early time
points postinjection (1 hr), viruses were labeled with fluo-
rescent Alexa Fluor 488 (green). To deplete macrophages,
200 ll of PBS or liposome-encapsulated clodronate (di-
chloromethylene diphosphonate [Cl2MDP], or clodronate,
was a gift from Roche Diagnostics, Mannheim, Germany)
was administered 48 hr before delivery of labeled viruses
(van Rooijen and van Kesteren-Hendrikx, 2003). Blood
samples were obtained 6 or 24 hr postinjection. Hematolo-
gical profiles (24 hr) and liver transaminases (96 hr), aspar-
tate aminotransferase (AST), and alanine aminotransferase
(ALT) were determined by the Clinical Veterinary Bio-
chemistry Service at the Facultat de Veterina`ria, Universitat
Auto`noma de Barcelona (Barcelona, Spain).
MCF10-CA1a human breast carcinoma cells (2· 106) were
injected subcutaneously into the left and right flanks of CD1
nude female mice. When tumors reached *250mm3 ani-
mals were randomized and matched according to average
tumor volumes (n = 8 per group). Animals were injected
intravenously with a single dose of PBS (control), or with
replication-competent virus Ad5-EGFPWT (2· 1010 VP),
Ad5-EGFPA20 (2 · 1010 or 4· 1010 VP), or Ad5-477dlTAYTA20
(2· 1010 or 4· 1010 VP). Ad5-EGFPWT at the higher dose of
4· 1010 VP could not be administered because of the
FIG. 1. (A) Knob477dlTAYTA20 does not bind to CAR. KnobA20 and Knob477dlTAYTA20 were used to competitively inhibit
the entry of Ad5-EGFPWT into CHO-CAR cells. Cells were preincubated with KnobA20 or Knob477dlTAYTA20 (0.001–100lg/
105 cells) and infected with Ad5-EGFPWT, and EGFP transgene expression was measured by flow cytometry (*22 hr post-
infection). Inhibition was evaluated by expressing EGFP-positive knob-treated cells as a percentage relative to untreated
control (uninhibited Ad5-EGFPWT entry). (B) Knob477dlTAYTA20 retains its functional ability to bind to avb6. Knob477dl-
TAYTA20 blocks avb6 on the surface of BT-20 cells, inhibiting the binding of an avb6-specific antibody (53A.2) in a dose-
dependent manner. Cells were preincubated for 1 hr at 4C with Knob477dlTAYTA20 (0.0001–10 lg/105 cells). KnobWT was
included as a negative control at a single concentration (10lg/105 cells). 53A.2 was added to cells, and its binding was
detected by flow cytometry. Untreated cells were taken as 100% fluorescence and all other values are expressed relative to
this. (C) Ad5-477dlTAYTA20 is ablated for CAR-mediated transduction in CHO-CAR cells. CHO-CAR cells were incubated
with Ad5-EGFPWT, Ad5-EGFPA20, or Ad5-477dlTAYTA20 for 2 hr at 37C (MOI, 10 PFU/cell). Twenty-two hours postin-
fection, transduction was measured by flow cytometry as the percentage EGFP-positive cells. (D) Ad5-477dlTAYTA20 has
transduction levels comparable to Ad5-EGFPA20 in avb6-expressing carcinoma cells. The transduction efficiency of each virus
was assessed after infection at an MOI of 10 (PFU/cell). Histogram shows the percentage EGFP-positive cells obtained by
flow cytometry. (E and F) A20-modified viruses have superior tumor cell-killing capacity in (E) CAOV3 and (F)MCF10-CA1a
human carcinoma cells compared with Ad5-EGFPWT. Cytotoxicity assays (120 hr postinfection) were performed with virus
concentrations ranging from 0.0001 to 100 PFU/cell. Mean percentage survival was expressed as a percentage of uninfected
cells (uninfected cells are represented on the x axis as 0). EC50 values for (E) and (F) are displayed in Table 3. Data represent
means – SD of triplicate samples and are representative of two independent experiments carried out on different occasions.
(G) Hemagglutination of human erythrocytes. Fifty microliters of a 2% erythrocyte suspension was incubated at 37C
for 2 hr with various concentrations of viral particles (Ad5-EGFPWT, Ad5-EGFPA20, or Ad5-477dlTAYTA20). The extent
of hemagglutination was scored according to the method of Cichon and colleagues (2003). + control, 0.1% Triton X-100;
– control, PBS.
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profound hepatocyte transduction, toxicity, and morbidity
induced by day 4 postinjection. Tumor volumes and mouse
morbidity (e.g., body weight, tumor ulceration) were moni-
tored three times per week. Tumor volume was calculated
according to the equation V (mm3)= p/6 ·W (width) ·L2
(length). The percentage of growth was defined as [(VX -
V0)/V0] · 100, where VX is the tumor volume on the day of
measurement and V0 is the tumor volume on day 0 (Cascallo
et al., 2007). All animals were killed once the tumors of the
PBS control group approached 1.4 cm3.
Viral biodistribution and immunohistochemistry
Viral genomes were quantified from tissue as described
(Coughlan et al., 2009). For 1-hr experiments with Alexa Fluor
488-labeled virus, immunohistochemistry was carried out on
frozen liver and spleen sections, using antibodies to macro-
phage marker F4/80 (KCs) and the splenic marginal zone
macrophage marker MARCO (macrophage receptor with a
collagenous structure) (Table 1) as described (Alba et al., 2010).
Frozen liver sections (24 and 96hr postinjection) were stained
with an anti-E1A antibody (Table 1) as described previously
(Coughlan et al., 2009, 2010). Images were captured with
fluorescence filters for fluorescein isothiocyanate (FITC) and
tetramethylrhodamine isothiocyanate (TRITC) on an Olympus
BX60 fluorescence microscope (·10 or·60 oil immersion ob-
jective). Images were acquired and merged, using Cell^M
software (Olympus, UK), and processed to adjust brightness
and contrast, using ImageJ (National Institutes of Health,
Bethesda, MD). Adjustments were applied equally to all
compared images.
Hematoxylin and eosin (H&E) staining was carried out by
the Pathology Service at Barts Cancer Institute (London, UK).
Staining for E1A or CD31 in paraffin-embedded MCF10-
CA1a tumor xenografts was performed as follows: sections
were dewaxed and rehydrated, and antigen retrieval was
performed with boiling sodium citrate (pH 6.0). Endogenous
avidin–biotin activity was blocked with a commercial kit
from Vector Laboratories (Burlingame, CA). Sections were
blocked for 30min at 37C in blocking buffer (PBS with 1%
[w/v] bovine serum albumin [BSA], 10% normal horse se-
rum, and 0.1% [v/v] Triton X-100). Primary anti-E1A (rabbit
polyclonal IgG; 13S-5) or anti-CD31 (rat IgG2a; SZ31) anti-
bodies were incubated with sections for 1 hr at room tem-
perature. Secondary detection was achieved with an ABC
Universal Elite kit (E1A) or ABC standard kit (CD31), fol-
lowed by application of a 3,3¢-diaminobenzidine (DAB)
peroxidase substrate kit (all kits from Vector Laboratories)
for chromogenic color development. Nuclei were counter-
stained with Mayer’s hematoxylin, dehydrated by expo-
sure to an alcohol gradient, and mounted on slides.
Immunostaining for avb6 integrin (mouse IgG; 62G2) was
performed as described previously (Clark et al., 2011). Anti-
gen retrieval for avb6 integrin or pan-cytokeratin (AE1/AE2)
was achieved with enzymatic pepsin or proteinase K, re-
spectively. Both antibodies were used with a M.O.M.
blocking kit (Vector Laboratories). Further details on anti-
bodies used are outlined in Table 1. Staining was imaged
with an Olympus BX40, QImaging MicroPublisher 3.3 RTV
microscope/camera and images were acquired with QCap-
ture Pro 6.0 software.
Quantification of immunohistochemistry
E1A-, avb6-, CD31-, and cytokeratin-positive staining was
quantified with Image-Pro Analyzer 7.0 software (Media
Cybernetics, Bethesda, MD), as recommended (http://www
.mediacy.com/index.aspx?page = IP_measure_and_classify).
The integrated optical density (IOD, equal to the area ·
average intensity) of unprocessed, entire TIFF images was
calculated using the manual intensity range selection option
and the histogram-based index. Regions of positive staining
were identified by manually selecting segmentation, using
the color cube tool. Statistics were automatically generated
for each image and the percent positive staining was deter-
mined by the following formula: Sum IOD of color cube/
sum IOD of histogram · 100. The proportions of necrotic
regions and stroma were estimated by manually delineating
defined regions within H&E images and expressing the area
as a percentage of the total area of each image. Approxi-
mately 20–30 tumor sections from various animals (n= 4–6
animals) were used for each image analysis quantification.
Statistical analysis
In vitro data show means – SD of triplicate samples and are
representative of two independent experiments carried out
on different occasions. In vivo data show means – SEM of
n= 5–8 animals per group (indicated in the figure legends).
Statistical significance was determined by unpaired Student
t test (*p< 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001; NS, not
statistically significant [p> 0.05]).
Table 2. Surface Receptor Expression
CAR avb6
Percent
positive cells
Geo.
mean
Percent
positive cells
Geo.
mean
BT-20 5.26 14.79 97.30 32.69
CAOV3 6.50 7.83 24.90 22.13
CHO-CAR 93.12 354.48 0.51 19.06
DX3-b6 5.72 12.74 96.06 66.90
HEK293-b6 99.31 162.72 97.11 135.51
JH293-b6 97.76 96.97 99.17 114.13
MCF10-CA1a 61.21 14.77 99.66 76.12
CAR, coxsackievirus–adenovirus receptor; Geo. mean, geometric
mean fluorescence.
aPercent positive statistics (1 · 104 gated events) were collected by
flow cytometry, using single-parameter histograms (FL1-H). Nega-
tive control isotype IgG fluorescence values were subtracted from
the geometric mean fluorescence of the test antibody (Rmc B/53A.2).
Isotype controls: mouse IgG1 for anti-CAR (RmcB) and rat IgG2a for
anti-avb6 (53A.2).
Table 3. EC50 Values
a
MCF 10-CA1a CAOV3
Ad5-EGFPWT 0.56 3.09
Ad5-EGFPA20 0.03 0.24
Ad5-477 dlTAYTA20 0.07 0.37
aEC50 values represent half the maximal effective concentration of
virus per cell. Viability was assessed by MTT assay and results
analyzed by nonlinear regression fitted to a sigmoidal curve. Values
expressed as plaque-forming units (PFU)/cell.
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Results
Fiber modifications (Y477AdlTAYT) ablate CAR
binding but do not affect A20-mediated entry
via avb6 integrin
Recombinant fiber knob protein blocking of Ad trans-
duction is a well-established assay. KnobWT previously has
been shown to inhibit Ad5 with a median inhibitory con-
centration (IC50) of 0.115lg/10
5 cells (Kirby et al., 2000). We
tested the ability of KnobA20 and Knob477dlTAYTA20 to
block the CAR-mediated entry of Ad5-EGFPWT into CHO-
CAR cells (Fig. 1A). Preincubation of cells with KnobA20 in-
hibited Ad5-EGFPWT transduction at an IC50 of 0.34 lg/10
5
cells (Coughlan et al., 2009) close to the previously published
IC50 for Ad5. Knob477dlTAYTA20 failed to inhibit Ad5-
EGFPWT infection significantly at concentrations up to
£ 100 lg/105 cells.
In a separate experiment, Knob477dlTAYTA20 was tested
for its ability to bind avb6 in vitro (Fig. 1B) and inhibit the
subsequent binding of an avb6-specific antibody (53A.2). We
have previously described that KnobA20 inhibits binding of
53A.2 to avb6 with an IC50 of 0.03lg/10
5 cells (Coughlan et al.,
FIG. 2. Comparative transduction of (A–C) CHO-K1 cells and (D) modified CHO cells by viruses – FIX, FX, or modified
heparins. Ad5:FIX/FX interactions promote viral transduction via engagement with HSPGs, and therefore we used porcine
heparin and de-N- and de-O-sulfated heparins (25 lg/ml) as inhibitors for blood factor-mediated entry into CHO-K1 cells
(A–C). Cells were infected with virus alone (MOI, 10) or with virus coincubated with physiological concentrations of FIX or
FX (5 and 10lg/ml, respectively). Heparins were added to cells before virus:FIX/FX complexes formed. Data are presented
as percent EGFP gene transfer, assessed by flow cytometry. (D) Comparative transduction of CHO-K1, CHO-pgsA745, CHO-
pgsE606, and CHO-pgsF17 cells. To dissect out the enhanced transduction of Ad5-477dlTAYTA20 relative to Ad5-EGFPWT
and Ad5-EGFPA20 in CHO-K1 cells, we compared the entry of each virus into CHO-K1 cells and CHO cells that lack HSPS or
their side chains. Data are representative of two independent repeat experiments, using triplicate samples (n= 3).
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2009). Knob477dlTAYTA20 inhibited 53A.2 binding at an
identical concentration, indicating that the introduced muta-
tions did not affect the interaction between the A20 peptide
and avb6 integrin. KnobWT negative control was unable to
block 53A.2 binding at a high concentration (10lg/105 cells)
and did not differ from untreated cells ( p= 0.168).
We confirmed that the CAR-binding capacity of the
Ad5-477dlTAYTA20 virus was ablated by assessing its
transduction on CHO-CAR cells (Fig. 1C). As expected,
Ad5 transduction was high (*80%) whereas in contrast,
Ad5-477dlTAYTA20 levels were low (*10%), confirming
that the CAR-binding capacity was ablated in this virus.
CAR-mediated transduction with Ad5-EGFPA20 was slightly
impaired relative to Ad5-EGFPWT, suggesting that the A20
insertion interferes to some degree with the fiber knob:CAR
interaction.
Using a panel of low-CAR, high-avb6 human carcinoma
cell lines (Table 2), the transduction efficiency of Ad5-
477dlTAYTA20 was compared with those of Ad5-EGFPWT
and Ad5-EGFPA20 (Fig. 1D). Ad5-477dlTAYTA20 displayed
comparable, or superior, transduction efficiency compared
with Ad5-EGFPA20, and both were significantly better than
Ad5-EGFPWT at an MOI of 10 (PFU/cell). We also verified
that Ad5-477dlTAYTA20 exhibited enhanced tumor cell kill-
ing relative to Ad5-EGFPWT (Fig. 1E and F). Comparative
cytotoxicity profiles (MTT assay), obtained 120 hr postinfec-
tion, showed that Ad5-EGFPA20 and Ad5-477dlTAYTA20 had
lower EC50 values (Table 3) compared with Ad5-EGFPWT.
Collectively, these data confirmed that the A20 peptide,
when combined with the introduced mutations, retained its
full ability to interact with avb6.
It is now known that Ad5 agglutinates human erythrocytes
via CAR (Nicol et al., 2004; Carlisle et al., 2009; Seiradake et al.,
2009). This fact has prompted some concerns over the relevance
of performing tumor-targeting studies in mice, as murine
erythrocytes do not express CAR. Ad5-477dlTAYTA20 did not
agglutinate human erythrocytes, even at the highest concen-
tration of virus (Fig. 1G), presumably as a result of the intro-
duced Y477A mutation at a critical CAR-binding residue. With
the exception of the highest dose, Ad5-EGFPA20 also failed to
agglutinate human erythrocytes, possibly because of its slightly
reduced interaction with CAR (see Fig. 1A and C).
In vitro characterization of viral entry
with or without coagulation factors and modified heparins
Coagulation factor-mediated hepatocyte transduction has
been shown to result from engagement with HSPGs, pref-
erentially those with sulfated side chains (Bradshaw et al.,
2010). FIX/FX-mediated infectivity enhancement was as-
sessed, using HSPG-expressing CHO-K1 cells (Fig. 2A–C)
and CHO cells with deficiencies in the synthesis of HS side
chains (Fig. 2D). Transduction of the Ad5:FX complex can be
inhibited by preincubation of CHO-K1 cells with porcine, but
not modified, heparins (Bradshaw et al., 2010). Transduction
assays on CHO-K1 cells compared Ad5-EGFPWT (Fig. 2A),
Ad5-EGFPA20 (Fig. 2B), and Ad5-477dlTAYTA20 (Fig. 2C)–
FIX/FX and porcine heparin, de-N-sulfated heparin, and de-
O-sulfated heparin.
FIX and FX enhanced transduction of Ad5-EGFPWT
*5-fold and > 30-fold, respectively (Fig. 2A), and this was
ablated by both heparin and de-N-sulfated heparin, but not
by de-O-sulfated heparin. The FX effect was completely in-
hibited by heparin, but not by de-N- or de-O-sulfated hep-
arin. Transduction of CHO-K1 cells with Ad5-EGFPA20 was
enhanced marginally (*2-fold) by FIX, although this was
not found to be statistically significant (Fig. 2B). FX signifi-
cantly enhanced the transduction of Ad5-EGFPA20 (*30-fold
increase; p< 0.0001) and, similar to Ad5-EGFPWT, this effect
was inhibited by heparin but not by de-N- or de-O-sulfated
heparin. Unexpectedly, Ad5-477dlTAYTA20 mediated *15%
transduction in CHO-K1 cells (Fig. 2C), compared with < 2%
transduction levels detected with Ad5-EGFPWT or Ad5-
EGFPA20 (Fig. 2A and B). This was inhibited completely
when cells were coincubated with heparin, de-N-sulfated
heparin, and de-O-sulfated heparin. FX enhanced the entry
of Ad5-477dlTAYTA20 in a manner similar to Ad5-EGFPWT
and Ad5-EGFPA20. No significant infectivity enhancement
was observed on coincubation of Ad5-477dlTAYTA20 with
FIX (Fig. 2C; p = 0.11).
The transduction of each virus was assessed in CHO cell
derivates (CHO-pgsA745, CHO-pgsE606, and CHO-pgsF17),
which are deficient in HSPGs or defined side-chain modifi-
cations (Fig. 2D). Ad5-477dlTAYTA20 entry was reduced
dramatically, in CHO-pgsA745 cells, which are completely
FIG. 3. Analysis of viral genome accumulation in liver and spleen 1hr postinjection (4.0· 1010 VP/mouse). BALB/c immu-
nocompetent mice were injected intravenously with PBS, 4· 1010 VP of Alexa Fluor 488-labeled Ad5-EGFPWT (Ad5-488), Ad5-
EGFPA20 (AdA20-488), or Ad5-477dlTAYTA20 (477YT-488). To deplete macrophages, separate groups of mice were pretreated
with PBS (–Cl2MBP) or clodronate liposomes (+Cl2MBP) 48hr before virus injection. Absolute viral genomes were quantified by
TaqMan real-time quantitative qPCR, using a probe to detect the hexon region of the genome. (A) Viral genome accumulation in
liver. (B) Quantification of Alexa Fluor 488-labeled particles in tissue sections. The number of Alexa Fluor 488-labeled viral
particles (green) in liver sections was quantified automatically from 6 to 10 separate images taken at · 60 magnification, using
ImageJ analysis software. (C) Immunohistochemistry of liver tissue 1hr after intravenous delivery of Alexa Fluor 488-labeled
virus. Frozen liver sections (4lm) were stained with anti-F4/80 antibody (red) to visualize Kupffer cells (KCs); nuclei were
counterstained with DAPI (blue) and Alexa Fluor 488-labeled viral particles can be seen in green. Left: Virus-alone image and
F4/80-merged image for untreated (–Cl2MBP) animals. Right: Livers of treated (+Cl2MBP) animals, with a highlighted region of
interest magnified and indicated by white arrows. (D) Immunohistochemistry of spleen tissue 1hr after intravenous delivery of
Alexa Fluor 488-labeled virus. Frozen tissue sections (6lm) were stained with an anti-MARCO antibody (red) to visualize
scavenging marginal zone macrophages surrounding the white pulp. Viral particles can be seen in green and nuclei are
counterstained with DAPI (blue). Regions of colocalization can be seen in yellow. Left: MARCO-merged image for untreated
(–Cl2MBP) animals, with a highlighted region of interest magnified. Right: Merged image of treated (+Cl2MBP) animals, with a
highlighted region of interest magnified. Note the absence of MARCO+ cells in Cl2MBP-treated animals. (E) Viral genome
accumulation in spleen. (F) Quantification of Alexa Fluor 488-labeled particles in spleen sections. The number of Alexa Fluor
488-labeled viral particles (green) in spleen sections was quantified automatically from 6 to 10 separate images taken at · 40
magnification, using ImageJ analysis software. Data represent means– SEM (n= 5 mice). *p< 0.05; ***p£ 0.001.
‰
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deficient in HSPGs, whereas transduction was not affected
by the absence of O- or N-sulfated HS side chains (CHO-
pgsE606) or 2-O-sulfated residues (CHO-pgsF17).
Investigation of virus accumulation at early time points
(1 hr) after intravenous delivery
Ad5-EGFPA20 displays reduced hepatotropism compared
with Ad5-EGFPWT, 72 hr postinjection (Coughlan et al., 2009).
These prior studies were performed in tumor-bearing im-
munodeficient mice with no examination of liver uptake at
earlier time points. Here, we injected immunocompetent
mice with 4 · 1010 VP of Alexa Fluor 488-labeled viruses:
Ad5-EGFPWT (Ad5-488), Ad5-EGFPA20 (AdA20-488), or
Ad5-477dlTAYTA20 (477YT-488). Viral genome distribution
was quantified and virus colocalization was established 1 hr
postinjection. We previously suggested that the reduced liver
tropism we observed with Ad5-EGFPA20 may be due to
differential interactions with scavenging macrophages after
intravenous delivery (Coughlan et al., 2009). To investigate
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this possibility, separate groups of animals were pretreated
with clodronate (Cl2MBP)-containing liposomes to eliminate
macrophages.
We observed significantly fewer Ad5-EGFPA20 (> 10-fold
fewer; p < 0.024) and Ad5-477dlTAYTA20 ( > 60-fold fewer;
p < 0.015) genomes in the liver when compared with Ad5-
EGFPWT (Fig. 3A). However, pretreatment with Cl2MBP did
not alter the early uptake of any virus in the liver relative to
untreated groups. In untreated animals (–Cl2MBP) virus
(green) colocalized with F4/80 + (red) hepatic macrophages
(Fig. 3C, left), although the density of viral particles within
these KCs appeared less concentrated for both Ad5-EGFPA20
and, especially, Ad5-477dlTAYTA20. Quantification of Alexa
Fluor 488-labeled viral particles per field of view in multiple
liver sections, using ImageJ image analysis software, con-
firmed the reduced accumulation of both A20 viruses in the
liver (Fig. 3B). In the livers of pretreated animals (+Cl2MBP),
F4/80 + macrophages were effectively eliminated and the
pattern of viral particle distribution was broad and diffuse
(Fig. 3C, right). We detected Ad5-EGFPWT and Ad5-EGFPA20
particles scattered over the surface of the liver parenchyma,
although with considerably fewer Ad5-EGFPA20 particles.
Ad5-477dlTAYTA20 was not detected in any liver sections of
Cl2MBP-treated animals. These data were also further con-
firmed by image analysis and quantification (Fig. 3B).
Lower levels of Ad5-EGFPA20 and Ad5-477dlTAYTA20
genomes were detected in the spleen compared with Ad5-
EGFPWT (Fig. 3E). Evidence has highlighted the importance
of the spleen as a major site for the induction of innate im-
mune responses directed toward intravenously delivered
Ads (Zhang et al., 2001; Koizumi et al., 2007). Therefore,
vectors that have limited splenic uptake may elicit reduced
inflammatory responses and subsequent toxicity. In animals
pretreated with Cl2MBP liposomes there were slight in-
creases in the level of qPCR-detected virions. As reported
elsewhere (Di Paolo et al., 2009a), we detected Ad5-EGFPWT
and Ad5-EGFPA20 colocalized with MARCO
+ scavenging
macrophages, which reside in the marginal zone (MZ) of the
spleen (Fig. 3D, left). Pretreatment with Cl2MBP completely
eliminated the MARCO + MZ macrophage population (Alba
et al., 2010), but diffuse Ad5-EGFPWT and Ad5-EGFPA20 viral
particles were clearly detectable in a similar anatomical
location to the MZ, surrounding the white pulp (Fig. 3D,
right). Viral particles did not appear to colocalize with
4¢,6-diamidino-2-phenylindole (DAPI), suggesting that viri-
ons were largely extracellular at this time point. Images were
quantified by ImageJ analysis for the number of Alexa Fluor
488-labeled viral particles in multiple sections from various
animals (Fig. 3F).
Assessment of viral genome distribution
and E1A viral gene expression 24 hr
after intravenous delivery (4.0 ·1010 VP/mouse)
Absolute genome copy numbers in the liver were quan-
tified as described previously (Fig. 4A). Approximately
17-fold fewer Ad5-EGFPA20 and *27-fold fewer Ad5-
477dlTAYTA20 genomes were detected in liver compared
with Ad5-EGFPWT ( p< 0.0001 for both). We also detected
*2-fold fewer Ad5-EGFPA20 and Ad5-477dlTAYTA20 ge-
nomes in spleen relative to Ad5-EGFPWT ( p= 0.013 and
p = 0.007, respectively). Substantially lower levels of E1A
expression also were detected in the livers of groups that had
received the A20-retargeted viruses (Fig. 4B).
Quantification of inflammatory (6 hr) and hematological
(24 hr) profiles after intravenous delivery of virus
(4.0 ·1010 VP/mouse)
We wished to obtain inflammatory and hematological
profiles for each virus after intravenous delivery. In-
travenous delivery of Ad5 has been shown to induce rapid
innate immune responses, with the release of various
proinflammatory cytokines and chemokines (Lieber et al.,
1997; Zhang et al., 2001; Shayakhmetov et al., 2005; Di Paolo
et al., 2009a)*6–12 hr postinfection (Lieber et al., 1997). Ad5-
EGFPWT elevated serum cytokine/chemokines significantly
6 hr postinjection (Fig. 4C). IL-6 was elevated *22-fold
( p < 0.0001) in mice treated with Ad5-EGFPWT whereas the
levels of IL-6 induced by Ad5-EGFPA20 and Ad5-477dlTAY-
TA20 were substantially lower. RANTES and IFN-c levels
were elevated above baseline in all virus-treated cohorts
( p < 0.01). However, Ad5-EGFPWT induced substantially
higher levels of RANTES (*13-fold elevation; p < 0.0001) and
IFN-c (*1400-fold; p< 0.0001) compared with Ad5-EGFPA20
and Ad5-477dlTAYTA20 (*4-fold elevation [p< 0.004] and
*7-fold elevation [p= 0.001], respectively). No significant
elevation of TNF-a levels occurred for any virus ( p> 0.05 for
all), as reported by others (Zhang et al., 2001).
Systemic administration of Ad5 induces acute transient
thrombocytopenia, which occurs between 5min and 24 hr
postinjection in mice (Othman et al., 2007). A full hemato-
logical profile for each of the treatment groups (24 hr) was
assessed (Fig. 4D). Interestingly, only Ad5-EGFPWT induced
thrombocytopenia (*2-fold reduction in total platelet count;
p= 0.003), whereas the total platelet counts of animals treated
with Ad5-EGFPA20 or Ad5-477dlTAYTA20 were not altered,
being similar to the PBS control group ( p= 0.228 and
p= 0.213, respectively). Total monocyte and lymphocyte
levels were reduced in all virus-treated cohorts. Total neu-
trophil levels were reduced in the Ad5-EGFPWT-treated
group. No significant differences were observed in overall
basophil or eosinophil populations (data not shown).
Quantification of viral genome distribution
and toxicity 96 hr postinjection (4.0 ·1010 VP/mouse)
We chose a late time point postinjection for analysis of
toxicity and acute hepatic injury. Separate groups of animals
were killed 96 hr postinjection, and their livers and spleens
were harvested for analysis (Fig. 5A). Absolute viral ge-
nomes were quantified by qPCR. As expected, significant
amounts of Ad5-EGFPWT were detected in the liver but,
in agreement with findings at 1 and 24 hr, we detected
*7.5-fold fewer Ad5-EGFPA20 ( p= 0.002), and *5.5-fold
fewer Ad-477dlTAYTA20 ( p = 0.002) genomes. Ad5-EGFPA20
and Ad5477dlTAYTA20 genome levels in the spleen were also
*2.6-fold lower than Ad5-EGFPWT ( p= 0.0008 and p= 0.007,
respectively). No differences were noted between Ad5-
EGFPA20- and Ad5-477dlTAYTA20-treated cohorts ( p= 0.929).
By immunohistochemistry, we observed a clear reduction
in levels of E1A expression in the livers of Ad5-EGFPA20-
and Ad5-477dlTAYTA20-treated groups, compared with the
Ad5-EGFPWT group (Fig. 5B), correlating with our findings
at 24 hr.
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H&E staining of liver sections revealed distinct histologi-
cal differences between Ad5-EGFPWT- and Ad5-EGFPA20/
Ad5-477dlTAYTA20-treated groups (Fig. 5C). The livers of
mice administered Ad5-EGFPWT showed striking hepatocyte
atypia, with ballooning degeneration of cells and individual
cell necrosis. A prominent periportal lymphocytic inflam-
matory infiltrate was present in the livers of animals that
received Ad5-EGFPWT but not those that received Ad5-
EGFPA20 or Ad5-477dlTAYTA20. Liver transaminase levels
were altered significantly between the Ad5-EGFPWT group
FIG. 4. (A) Quantification of
viral genomes in murine liver
24 hr after intravenous deliv-
ery (4.0 · 1010 VP/mouse).
BALB/c immunocompetent
mice were injected intrave-
nously with PBS, Ad5-
EGFPWT, Ad5-EGFPA20, or
Ad5-477dlTAYTA20. Mice
were killed 24 hr postinjec-
tion, necropsy was per-
formed, and total DNA was
extracted from liver tissue.
Absolute viral genomes were
quantified by qPCR, using a
probe to detect the hexon re-
gion of the genome. (B) Im-
munostaining (E1A) of frozen
liver tissue 24 hr after intra-
venous delivery of virus.
Frozen tissue sections (4lm)
were stained with an anti-
E1A antibody (green). Sec-
tions were visualized at a
magnification of · 20, using
an Olympus BX60 fluores-
cence microscope, and images
were acquired with SPOT
Advanced software (SPOT
Imaging Solutions, Sterling
Heights, MI). (C) Quantifica-
tion of serum cytokines after
intravenous delivery of virus.
Serum samples were obtained
from the 24-hr cohort of ani-
mals, 6 hr postinjection. Ser-
um cytokines IL-6, RANTES,
IFN-c, and TNF-a were
quantified by fluorescent
bead, sandwich ELISA-based
technology (FlowCytomix;
Bender MedSystems). Sam-
ples were acquired by flow
cytometry, and analyzed with
FlowCytomix Pro 2.2 soft-
ware. (D) Hematological pro-
files obtained 24 hr after
intravenous delivery of virus.
Whole blood samples (250ll)
were obtained immediately
postmortem. Hematological
profiles were assessed at the
Clinical Veterinary Biochem-
istry Service at the Facultat de
Veterina`ria, Universitat Au-
to`noma de Barcelona. Data
represent means – SEM (n= 6–
8 mice). *p< 0.05; **p£ 0.01;
***p £ 0.001; ****p £ 0.0001; NS,
not significant.
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and A20-retargeted groups (Fig. 5D and E). The Ad5-
EGFPWT-treated group displayed markedly elevated ALT
levels, *35-fold above basal PBS levels ( p< 0.0001). In com-
parison, the elevation of ALT in the Ad5-EGFPA20- and Ad5-
477dlTAYTA20-treated groups was only *4.5-fold ( p= 0.027)
and *9-fold ( p= 0.008), respectively. AST levels were also
similarly affected by each virus (Fig. 5E). Ad5-EGFPWT
treatment induced high levels of AST, *15-fold above the
basal level ( p< 0.0001). However, neither the Ad5-EGFPA20
nor Ad5-477dlTAYTA20 group presented an elevated AST
level compared with the basal PBS level ( p> 0.05 for both).
Comparison of antitumoral efficacy of intravenously
delivered Ad5-EGFPWT, Ad5-EGFPA20, and
Ad5-477dlTAYTA20 and measurement of therapeutic
outcome in MCF10-CA1a xenograft model
We tested the antitumoral efficacy of Ad5-EGFPWT,
Ad5-EGFPA20, and Ad5-477dlTAYTA20 (2 · 1010 VP) after
intravenous delivery in immunodeficient mice, using a sub-
cutaneous MCF10-CA1a xenograft model (Fig. 6A and B). In
previous experiments, Ad5-EGFPA20 and Ad5-477dlTAYTA20
were well tolerated in immunocompetent mice at 4 · 1010 VP.
FIG. 5. (A) Quantification of viral genomes in murine liver 96hr after intravenous delivery (4.0· 1010 VP/mouse). BALB/c
immunocompetent mice were injected with PBS, Ad5-EGFPWT, Ad5-EGFPA20, or Ad5-477dlTAYTA20 by intravenous tail vein
injection. Mice were killed 96hr postinjection, necropsy was performed, and total DNA was extracted from liver tissue.
Absolute viral genomes were quantified by qPCR, using a probe to detect the hexon region of the genome. (B) Immunostaining
(E1A) of liver tissue after intravenous delivery of virus. Frozen tissue sections (4lm) were stained with an anti-E1A antibody
(green). Sections were visualized with an Olympus BX60 fluorescence microscope, and images were acquired with SPOT
Advanced software. (C)H&E staining of liver tissue after intravenous delivery of virus. Liver sections for each cohort (PBS, Ad5-
EGFPWT, Ad5-EGFPA20, and Ad5-477dlTAYTA20) were cut, stained with H&E, and assessed histopathologically. Sections were
photographed at a magnification of · 200, using an AxioCam MRc 5 camera (Zeiss, Oberkochen, Germany) and Axiovision
software (Zeiss, Germany). (D and E) Determination of toxicity after intravenous administration of virus. Blood samples were
obtained immediately postmortem (96hr), and (D) serum alanine transaminase (ALT) and (E) aspartate aminotransferase (AST)
levels were quantified for each group. Data represent means– SEM (n=5 mice). **p£ 0.01; ****p£ 0.0001; NS, not significant.
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FIG. 6. Antitumoral efficacy in MCF10-CA1a tumor xenograft model after single intravenous delivery of virus. MCF10-
CA1a xenografts were grown on the flanks of CD1 nude mice to an average volume of 250mm3. Animals were injected
intravenously with 2 · 1010 VP (all viruses), 4 · 1010 VP (Ad5-EGFPA20 or Ad5-477dlTAYTA20 only), or PBS, and tumor
volumes were recorded three times weekly until the experiment terminated (day 14 postinjection). Absolute tumor volumes
are shown in (A) and percent tumor growth is shown in (B). Tumor volumes and percent tumor growth were calculated as
described in Materials and Methods. (C) Immunohistochemistry of tumor sections for E1A, avb6, cytokeratin (CK), and CD31;
H&E staining is shown as well. Tumor sections (5 lm) were stained for viral antigen E1A, avb6 integrin, human cytokeratin
(carcinoma cells), and CD31 (murine endothelial cells); and with H&E. Examples of regions representing necrosis (N), stroma
(S), or tumor cells (T) are indicated on the H&E images. Images shown are representative of the group.
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Therefore, we also decided to test whether we could improve
the therapeutic outcome by using this increased dose of
vector.
The appropriate end point for solid tumor models is tu-
mor growth inhibition or tumor growth delay (Yarnold et al.,
1986; Wallace, 2000; Teicher, 2006). Using percent tumor
growth as a measure of therapeutic outcome, we found that
treatment with Ad5-477dlTAYTA20 slowed tumor growth
compared with PBS control (Fig. 6B). At 4 days postinjection,
both Ad5-477dlTAYTA20-treated groups displayed retarded
tumor growth compared with the Ad5-EGFPWT-treated an-
imals ( p= 0.02). Absolute tumor volumes also differed at this
time point; the Ad5-EGFPWT group had an average volume
of *428 versus *372/340mm3 for low-dose and high-dose
Ad5-477dlTAYTA20, respectively. Tumors of the group that
received the lower dose of 2 · 1010 VP continued to exhibit
slower growth than other treatment groups and differed
significantly from Ad5-EGFPWT again on day 9 postinjection
( p = 0.048). Again, the tumor volumes of both Ad5-
477dlTAYTA20 groups were reduced in comparison with the
Ad5-EGFPWT group (*507 and *496mm
3 vs. *549mm3).
However, differences in absolute tumor volume did not
reach significance because of the variable size of tumors
within the treatment groups. We had to terminate the
FIG. 7. Quantification of immunohistochemistry. Staining positive for (A) E1A, (B) avb6, (C) CD31, and (D) cytokeratin was
quantified with Image-Pro Analyzer 7.0 software (Media Cybernetics). Approximately 30 random tumor sections from
different animals (n = 4–6 animals) were used for analysis quantification of each group. Regions of (E) necrosis and (F) stroma
were also quantified with Image-Pro Analyzer 7.0. Data presented show means – SEM. *p< 0.05, ***p< 0.001 compared with
the Ad5 group.
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experiment on day 14 postinjection because of the large
volume and ulceration of tumors within the PBS control
group. We observed that although most treatment groups
had an improved therapeutic outcome versus the PBS-trea-
ted group, it was disappointing to note that there were no
differences between animals that received Ad5-EGFPWT and
animals that received A20-retargeted viruses ( p > 0.05).
We confirmed that the MCF10-CA1a tumors retained
high-level expression of the target receptor, avb6, by immu-
nohistochemistry (Fig. 6C). We then analyzed tumors from
several animals for viral antigen by E1A staining (Fig. 6C).
Reassuringly, the pattern of E1A staining in the A20-treated
groups correlated with regions of avb6
+ tumor cells. How-
ever, there were distinct differences in the extent of E1A
staining, as well as the overall dissemination and distribution
of viral gene expression throughout the tumor mass. Overall,
we observed greater amounts of E1A staining in the tumors
of Ad5-EGFPA20- and Ad5-477dlTAYTA20-treated animals
than in those of Ad5-EGFPWT-treated animals, suggesting
that these vectors had improved tumor targeting or, at least,
increased intratumoral replication in avb6
+ cells. We con-
firmed these observations by quantifying the amount of
E1A+ staining in tumor images, analyzing *30 tumor
images from 4–6 different animals for each separate group
(Fig. 7A). We found that Ad5-EGFPWT transduced approxi-
mately 1.5% of the tumor sections analyzed, whereas at the
same dose (2· 1010 VP), Ad5-EGFPA20 and Ad5-477dlTAY-
TA20 transduced*3.3 and 2.8%, respectively. After this type
of analysis, we found that the higher dose of both A20-
retargeted vectors displayed increased tumor transduction
when compared with the lower dose, with *4.6% E1A ex-
pression (both doses) detected versus *3.3 and 2.8%.
To eliminate the possibility that differences in the levels of
avb6 expression had affected the efficiency of tumor trans-
duction we also quantified the amount of avb6
+ staining in
tumor images, as described previously (Fig. 7B). There were
no differences in the percentage avb6
+ regions between
groups, with *16% of the tumors being composed of avb6
+
carcinoma cells. To assess the cellular composition of the
tumor, we also performed immunohistochemistry to detect
human cytokeratin (carcinoma cells) and murine CD31
(murine endothelial cells of the tumor vasculature). Ap-
proximately 26% of the tumors analyzed were cytokeratin + ,
demonstrating that there were both avb6-positive and avb6-
negative carcinoma cells within the tumor (Fig. 7C). The
amount of tumor vasculature did not differ between groups,
with CD31 + cells making up*3.3% of the tumors (Fig. 7D).
Therefore, we concluded that differences in tumor trans-
duction efficiency due to varying levels of viable tumor cells
or differential vascularization were unlikely. In H&E-stained
sections, we noted that areas of viable tumor cells were
separated by large areas of stromal tissue and extensive
regions of necrosis (Fig. 6C). Using image analysis software,
we estimated the proportion of necrotic and stromal cells
in tumor sections (Fig. 7E and F). On average, necrotic
areas and stromal cells made up a large proportion of the
tumor, representing *37 and 18% of the total tumor area,
respectively.
Inefficient intratumoral spread represents a major re-
maining challenge to the development of oncolytic viral
vectors. Stromal cells not only impart physical barriers to
virus spread, but cells of murine origin are not conducive to
productive adenoviral replication. The latter issue may affect
the interpretation of tumor efficacy studies performed in
mice. To attempt to overcome these limitations in the future,
it will be necessary to combine our fiber modifications with
transgenes that promote intratumoral spread.
Discussion
To refine the therapeutic index of intravenously delivered
Ad5 vectors, enhance potency, and improve therapeutic
outcome, it is widely accepted that transductional retarget-
ing will need to be combined with primary receptor de-
targeting, strategies to allow evasion of hepatocytes and
scavenging macrophages, as well as attempts to limit vector-
related toxicity. The intravenous delivery of Ad5 elicits a
robust inflammatory response, directed against both viral
particles and expressed genes (Lieber et al., 1997; Zhang et al.,
2001), which can limit transgene expression and reduce
therapeutic efficacy. Characteristic elevations in serum che-
mokines and cytokines contribute to the profound liver pa-
thology and toxicity associated with Ad5. Furthermore,
systemically delivered Ad vectors can cause hemodynamic
changes (Schiedner et al., 2003) and induce acute transient
thrombocytopenia (Othman et al., 2007), potentially exacer-
bating preexisting coagulopathic conditions in a clinical set-
ting. Differences between Ad5-mediated agglutination of
human and murine erythrocytes limit the translational rele-
vance of murine in vivo studies and may affect the success of
tumor-targeting strategies (Carlisle et al., 2009). Therefore,
tropism-modified Ad vectors that do not trigger these
side effects and have limited off-target interactions should
represent more promising candidates for future clinical
assessment.
In this study, we monitored the in vitro and in vivo
biological characteristics of an avb6-retargeted vector,
Ad5-477dlTAYTA20, compared with Ad5-EGFPWT and Ad5-
EGFPA20. Ad5-477dlTAYTA20 features the Y477dlTAYT
modification, reported to eliminate fiber interactions with
CAR and FIX/C4BP (Shayakhmetov et al., 2005). The CAR-
binding capacity of Ad5-477dlTAYTA20 was ablated and this
vector failed to agglutinate human erythrocytes, while re-
taining transduction efficiency comparable to that of Ad5-
EGFPA20 in a panel of avb6-expressing human carcinoma
cells. Ad5-477dlTAYTA20 also appeared to have acquired
some affinity for HSPGs in vitro, using them as additional
receptors for attachment/entry. Dysregulation of HSPGs
occurs in various pathophysiological conditions, including
cancer (Blackhall et al., 2001), and therefore enhanced inter-
action with HSPGs may be an attractive vector property for
targeting tumors in vivo. Relative to other organs, the liver is
particularly high in HSPGs with N- and O-sulfated side
chains (Vongchan et al., 2005), which have been shown to
promote Ad5:FX-mediated transduction in murine models
(Bradshaw et al., 2010). However, Ad5-477dlTAYTA20 trans-
duction via HSPGs in CHO-K1 cells was independent of
N- orO-sulfation (Fig. 2C) and we detected no increased HSPG-
mediated hepatocyte transduction when Ad5-477dlTAYTA20
was administered systemically.
The Ad5 hexon:FX interaction is the major determinant of
hepatocyte transduction in murine models (Parker et al.,
2006; Kalyuzhniy et al., 2008; Waddington et al., 2008).
Significant advances have resulted in the generation of
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FX-binding ablated vectors that completely avoid the liver,
thereby greatly improving Ad toxicity and safety (Alba et al.,
2010). Furthermore, it has been shown that FX-binding ab-
lated vectors can be successfully retargeted to CD46-positive
lung tissue by pseudotyping the fiber of Ad35 (Alba et al.,
2010). Coagulation factors have been shown to enhance the
transduction of human carcinoma lines in vitro and also have
been implicated in tumor transduction in vivo (Gimenez-
Alejandre et al., 2008; Shashkova et al., 2008; Coughlan et al.,
2009; Koski et al., 2009; Liu et al., 2009). Depletion of vitamin
K-dependent coagulation factors, using warfarin, can be
employed as a liver avoidance strategy, with the aim of in-
creasing the blood persistence and bioavailability for the
tumor. However, the level of success of this strategy has been
controversial, with some reports of enhanced tumor uptake
(Shashkova et al., 2008), and others describing negligible
changes or even reductions in tumor uptake (Gimenez-
Alejandre et al., 2008; Coughlan et al., 2009; Koski et al., 2009).
Importantly, reduced tumor uptake was observed with
integrin-retargeted Ads that feature the RGD-4C or
A20FMDV2 peptide in the HI loop of the fiber, suggesting
that integrin-directed retargeting is sensitive to the antic-
oagulative effects of warfarin in vivo. To date, it is unclear
precisely which warfarin-sensitive coagulation factor medi-
ates this effect. Selective depletion of FX alone, using X-bp
(factor X-binding protein), has been shown to improve
CD46-positive tumor transduction with an Ad5/35 vector
(Liu et al., 2009). This is reassuring for the future develop-
ment of tropism-modified Ads, although further assessment
and investigation will be required to determine whether this
also applies to integrin-retargeted Ads.
It seems possible that blood factors other than FX may
play some undefined role in Ad vector biodistribution or
tumor uptake. Shayakhmetov and colleagues first suggested
that FIX and C4BP bound to the Ad5 fiber knob domain, and
they reported that the Y477AdlTAYT mutation successfully
ablated this interaction (Shayakhmetov et al., 2005). Despite
lacking any FX-binding ablating modifications within the
hexon, the latter vector was shown to have reduced hepa-
totropism and limited accumulation in KCs after intravenous
delivery. Direct binding of FIX to the fiber of Ad5 has not
been conclusively confirmed, but it has been hypothesized
that a two-site FIX:Ad5 interacting model may be a possi-
bility (Kalyuzhniy et al., 2008). FIX has been shown previ-
ously to enhance the transduction of Ad5 in vitro
(Kalyuzhniy et al., 2008; Jonsson et al., 2009; Rogee et al.,
2010). We report that, unlike Ad5-EGFPWT, fiber-modified
vectors Ad5-EGFPA20 and Ad5-477dlTAYTA20 do not permit
FIX-mediated infectivity enhancement in vitro. Furthermore,
both A20-modified vectors display an altered in vivo phe-
notype, typified by reduced hepatotropism, limited induc-
tion of inflammatory cytokines, and reduced vector-related
toxicity.
Several reports exist of fiber-modified, fiber-pseudotyped,
or rare Ad species with reduced liver tropism (Denby et al.,
2004; Nakayama et al., 2006; Coughlan et al., 2009; Rogee
et al., 2010). Such effects may involve inefficient vector traf-
ficking, increased vector degradation, lack of available
functional receptors on the liver cell surface, or vector re-
targeting to other organs (Shayakhmetov et al., 2004). How-
ever, despite reduced hepatic transduction at later time
points, many of these vectors accumulate in the liver at levels
equivalent to Ad5 at early time points. By contrast, we
showed a significantly reduced amount of Ad5-EGFPA20 and
Ad5-477dlTAYTA20 viral genomes retained in the liver 1 hr,
as well as 24 and 96 hr, postinjection (Fig. 3A). Reasons for
the reduced early tropism of the A20-modified viruses cur-
rently are unclear.
Accumulation of Ads in the liver at early time points is a
result of synergistic mechanisms, involving not only KCs and
trapping of viral particles in hepatocytes, but also liver
sinusoidal endothelial cells (LSECs) and the space of Disse
(Di Paolo et al., 2009b; Ganesan et al., 2011). The exact order
of viral particle interaction with these diverse cell types, and
the relative importance of each cell type’s role in vector
clearance, is not fully understood and remains controversial.
Colocalization studies with KC marker F4/80 showed that
although all viruses accumulated within F4/80 + cells (Fig.
3C), the levels of both A20-modified viruses, especially Ad5-
477dlTAYTA20, were visibly reduced. Such data support the
original finding that a 477dlTAYT fiber-mutated virus,
Ad5mut, had reduced colocalization with KCs in vivo
(Shayakhmetov et al., 2005). The precise mechanisms un-
derlying KC-mediated recognition of virus are not clear,
although uptake of long-shafted Ads appears to be mediated
by the fiber knob, independently of CAR (Shayakhmetov
et al., 2004). Haisma and colleagues have demonstrated that
Ad5 uptake by primary KCs, via scavenging receptor A (SR-
A), can be inhibited by soluble Ad5 fiber knob protein in vitro
or preincubation of Ad5 with an anti-knob antibody before
injection intravenously, partially reducing accumulation
in KCs (Haisma et al., 2009). These findings may provide
support for the idea of a fiber knob:FIX interaction acting as a
‘‘bridge’’ for viral particle recognition by hepatic macro-
phages.
The release of proinflammatory molecules from KCs
function as chemotactic signals for infiltrating neutrophils as
well as contributing directly to hepatocyte damage (Lieber
et al., 1997). These factors have been associated with acute
hepatic injury and elevation of liver transaminases ALT and
AST (Muruve et al., 1999). Thus, viruses having reduced
interaction with KCs at early time points may have limited
hepatotoxicity. Here, animals administered Ad5-EGFPA20 or
Ad5-477dlTAYTA20 were well throughout the duration of the
experiment, with low-level induction of IL-6, RANTES, and
IFN-c (6 hr); no thrombocytopenia (24 hr); limited serum
transaminase elevations; and dramatically reduced accumu-
lation of virion DNA in the liver at the time of death (1, 24,
and 96 hr). In comparison, the Ad5-EGFPWT-treated groups
showed signs of cachexia, significantly elevated serum
transaminases, higher levels of viral DNA, and extensive
hepatic E1A expression. Histological examination of H&E-
stained liver sections revealed distinct differences between
the groups (96 hr), with Ad5-EGFPA20- and Ad5-477dlTAY-
TA20-treated groups showing an absence of periportal in-
flammatory infiltrate compared with Ad5-EGFPWT-treated
cohorts.
We previously published that Ad5-EGFPA20 has improved
uptake in avb6
+ tumor xenografts, 72 hr after intravenous
delivery (Coughlan et al., 2009). Ad5-477dlTAYTA20 also
displays this property in the same in vivo xenograft model
(our unpublished data). Thus, both A20-modified viruses
satisfy several of the criteria thought to be required for en-
hanced antitumoral efficacy, having improved uptake after
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intravenous delivery, reduced hepatotropism and toxicity,
and an improved in vivo safety profile. However, the efficacy
results were, largely, disappointing. Although we detected
reductions in tumor growth in animals treated with Ad5-
477dlTAYTA20 on days 4 and 9 postinjection, these effects
were not sustained for the duration of the experiment. On
completion of the experiment we did not detect any im-
provements in efficacy for A20-treated groups compared
with the Ad5-EGFPWT group, although there were im-
provements versus PBS-treated groups. Furthermore, re-
ductions in percent tumor growth were not improved by
increasing the dose. We chose a therapeutic dose of 4· 1010
VP for the A20-retargeted vectors on the basis of prior
evidence that this was well tolerated in immunocompetent
animals. At present, we do not know the maximal tolerated
dose of the A20-retargeted vectors; however, a dose of
5 · 1010 VP of wild-type replicating Ad5 generally is con-
sidered to be a lethal dose (Cawood et al., 2009). Because our
current viruses are fully replication competent, we were
cautious in selecting a dose for an efficacy experiment.
However, we cannot exclude the possibility that using a
higher dose could potentially improve the therapeutic index
of these vectors.
We verified that all tumors expressed the target receptor
avb6, and that overall levels did not differ between animal
groups (*16%). Assessment of E1A expression in the tumors
showed that there was efficient E1A expression within the
avb6
+ tumor cells of the A20-treated groups. Interestingly,
after quantification of E1A staining in images, both A20
vectors transduced tumor cells more efficiently that Ad5-
EGFPWT (*3.3 and 2.8% vs. 1.5%). Moreover, the amount of
E1A expression was further increased in the tumors of ani-
mals that received the higher dose of Ad5-EGFPA20 and Ad5-
477dlTAYTA20 (*4.6%). However, E1A staining within the
tumors was localized to islands of carcinoma cells separated
by large areas of stromal cells and regions of necrosis, sug-
gesting that the virus could not disseminate throughout the
tumor mass efficiently.
Poor intratumoral spread of oncolytic Ads is widely re-
ported and thus represents a further challenge to achieving
successful oncolytic viral therapy. Solid tumors contain
neoplastic cells, stromal fibroblasts, myofibroblasts, endo-
thelial cells, and immune cells, all of which interact with
various components of the extracellular matrix (ECM) to
affect migration, proliferation, and invasion (Wernert, 1997).
Poorly distributed vasculature within the tumor mass can
impede the uniform distribution and subsequent spread of
therapeutic delivery vehicles. Furthermore, dysregulation of
blood vessel formation or architecture, and the absence
of functional lymphatics, can contribute to the development
of a necrotic and hypoxic microenvironment. The presence of
expansive necrotic regions within the tumor mass negates
the therapeutic efficacy of oncolytic Ads, which require liv-
ing cells for replication and progeny production. In addition,
the physical nature of the tumor stroma and ECM imposes
barrier-like restrictions on the dissemination of virus
throughout the tumor. To assess the cellular composition of
MCF10-CA1a tumor xenografts, we quantified the overall
proportions of carcinoma cells, endothelial cells, stromal re-
gions, and necrotic areas within the tumors. In general, we
found that the tumor composition was similar between
groups, being largely composed of necrotic areas and stro-
ma, with only *26% tumor cells. At present we are exam-
ining whether these restrictions within this xenograft model
are responsible for limiting antitumoral efficacy. Further-
more, our constructs, in their current form, are not optimized
to overcome these barriers and will require further modifi-
cations in the future to address these possibilities.
Various Ad-based vector-engineering strategies currently
are being employed in an attempt to overcome some of these
restrictions. Dramatic improvements in efficacy have been
achieved with Ads when enhancing viral release and spread
through overexpression of the adenoviral death protein
(E3-ADP) or the viroporin-like activity of a truncated, mu-
tant E3-gp19K protein; or by using drugs, such as verapamil,
that augment virion release (Doronin et al., 2003; Gros et al.,
2008, 2010). Novel Ad-engineering strategies to enhance
potency include the incorporation of fusogenic proteins to
induce syncytium formation, or enzymatic transgenes that
digest/depolymerize components of the extracellular matrix,
thereby maximizing viral spread throughout the tumor
(Ganesh et al., 2007; Guedan et al., 2008, 2010, 2011). Such
agents have also demonstrated efficacy on pre- or coad-
ministration with virus (Ganesh et al., 2008). More recently,
in vitro bioselection of mutagenized Ad vectors in cancer-
associated fibroblasts has identified vectors with enhanced
release and cytotoxicity in stromal cells, resulting in im-
proved antitumoral activity (Puig-Saus et al., 2012).
It is important to note that the vectors used in this current
study do not feature any therapeutic transgene, nor do they
possess any transcriptional selectivity for tumor cells. They
are all completely replication-competent viruses. However,
we show that the introduction of defined mutations within
the fiber can improve the in vivo safety profile and the
therapeutic index. Therefore, both A20-modified vectors,
Ad5-EGFPA20 and Ad5-477dlTAYTA20, represent attractive
platform vectors for future investigation. Combination of
these capsid configurations with modifications that confer
replication selectivity (Oberg et al., 2011) or transgenes to
enhance intratumoral dissemination, would likely lead to
improvements in potency (Guedan et al., 2010, 2011). Fur-
thermore, an assessment of integrin-mediated targeting effi-
ciency in an FX-ablated background also is warranted.
Collectively, such modifications, together with use at a max-
imal dose, potentially could improve therapeutic outcome.
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